Founded in 2014, CMR Surgical is a private limited company backed by an international shareholder base. Versius is a modular and portable surgical robot designed to make it easier for hospitals and surgeons to give patients access to minimal access surgery, with compact design allowing it to move easily between departments and operating rooms with no dedicated OR required. CEO Massimiliano Colella delayed introducing the company's soft tissue surgery system in the U.S. by a year but says the improved robot now hitting the market was worth the wait.
Cyborg Score Rationale
CMR launched Versius in the U.S. following FDA clearance of the next-generation Versius Plus system in December 2025 for cholecystectomy. The company is pursuing 510(k) submissions for gastrointestinal surgery, gynecology, urology and general surgery, with clearances expected in 2026. Significant global adoption and strong competitive positioning against Intuitive's market dominance support the strong rating.
Top Insights
Over 45,000 patients treated globally (March 2026), establishing CMR as second most widely used robotic platform after Intuitive
In 2021, CMR raised $600M at $3B valuation from Escala Capital and SoftBank Vision Fund 2 in what was described as the world's largest private financing round in medtech
Strong NHS footprint with 20+ UK hospital partnerships as of October 2023, including major teaching hospitals in London, Cambridge, Edinburgh, and Cardiff
Versius reaches 45,000 cases globally as second most utilized platform; Versius Plus integrates fluorescence visualization system vLimeLite for real-time imaging capabilities
Named Competitors
Da Vinci — Market-leading surgical robotics platform with 20M+ patient procedures
Medicaroid — Japanese robotics manufacturer competing in minimally invasive surgery
Hugo — Medtronic's robotic-assisted surgery platform
Recent Developments
(March 2026) Announced 45,000 patient milestone and formal U.S. commercial launch at SAGES 2026 conference in Tampa
(December 2025) Received FDA 510(k) clearance for Versius Plus system for cholecystectomy procedures
(October 2024) Achieved initial FDA de novo clearance for first-generation Versius for soft tissue surgery
(September 2023) Raised $165 million to prepare for expanded market launches
Open the full interactive CMR Surgical report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.